**Trading Suspensions** - 601133 Bocheng Shares - 300506 ST Mingjia Hui

**Trading Resumptions** - 603496 Henway Technologies - 600735 ST Xinhua Jin - 300237 ST Meichen

**Major Corporate Developments**

**Tianjie Shares**: Lithium sulfide material preparation patent industrialization project has basically passed small-scale testing

Tianjie Shares announced unusual stock trading fluctuations, stating the company is advancing the industrialization of lithium sulfide material preparation patents. The project team consists of 7 R&D personnel, including 3 core researchers, with approximately 5 million yuan invested in R&D costs to date. The project has basically completed small-scale testing. Subsequently, the company needs to conduct scale-up experiments to analyze costs and industrial feasibility of candidate processes to determine seed processes, then enter pilot-scale phase for further scale-up of seed processes to comprehensively verify production stability, equipment compatibility, and complete customer sampling. Currently, the company's technology development remains in early stages, requiring lengthy process optimization and verification from patent to stable, mass-produced commercial products. Future emergence of superior, lower-cost solid electrolyte technology routes may weaken lithium sulfide technology's competitive advantages.

**Two-board limit Donghua Technology**: Tibet Zabuye Salt Lake green comprehensive development and utilization 10,000-ton battery-grade lithium carbonate project to officially commence production

Donghua Technology announced unusual stock trading fluctuations, stating that the Tibet Zabuye Salt Lake green comprehensive development and utilization 10,000-ton battery-grade lithium carbonate project, for which the company serves as EPC general contractor, successfully completed 120-hour functional assessment from September 20-24, 2025. The company released progress announcement on September 26. Completing functional assessment represents normal project progress, marking official production commencement.

**Bocheng Shares**: Planning to acquire 55% stake in Canshi, stock suspended

Bocheng Shares announced it is planning to acquire 55% equity in Shanghai Canshi Engineering Equipment Co., Ltd. through share issuance and cash payment, while planning to issue shares for supporting fundraising. Company stock will be suspended from market opening on September 30, 2025 (Tuesday), with expected suspension not exceeding 5 trading days. Bocheng Shares also announced receiving bid winner notification from a client, confirming the company as winning bidder for a clean-related project worth 325 million yuan (including tax).

**Dioo Micro**: Planning to acquire Rongpai equity, stock suspended

Dioo Micro announced it is planning to acquire equity in Rongpai Semiconductor (Shanghai) Co., Ltd. through share issuance and cash payment. Company stock was suspended from September 29, 2025 opening and will continue suspension from September 30, 2025 opening, with expected cumulative suspension not exceeding 10 trading days.

***ST Xingnong**: Investigated by CSRC for suspected information disclosure violations

*ST Xingnong announced receiving CSRC's "Case Filing Notice" for suspected information disclosure violations. According to relevant laws and regulations, CSRC decided to file a case against the company.

**Fulin Precision Engineering**: Plans to jointly participate in Jiangxi Shenghua capital increase with CATL

Fulin Precision Engineering announced that the company and CATL plan to jointly participate in capital increase of subsidiary Jiangxi Shenghua. The company plans to invest 1 billion yuan to subscribe for 813 million yuan of new registered capital, while CATL plans to invest 2.563 billion yuan to subscribe for 2.084 billion yuan of new registered capital. After completion, CATL will hold 51% equity in Jiangxi Shenghua, while the company will hold 47.4096%. This transaction will change the company's consolidated statement scope, making Jiangxi Shenghua a CATL-controlled subsidiary.

**Huace Film & TV**: Shareholder inquiry transfer price set at 7.42 yuan per share

Huace Film & TV announced that based on September 29, 2025 inquiry subscription results, the preliminary determined inquiry transfer price is 7.42 yuan per share. The inquiry transfer shares received full subscription, with 24 investors preliminarily determined as transferees for a total of 67.4706 million shares.

**Zhejiang Digital Culture**: Plans to acquire 6% stake in Zhejiang Publishing & Media for 1.176 billion yuan

Zhejiang Digital Culture announced plans to acquire 6% equity in Zhejiang Publishing & Media (601921) held by Zhejiang Publishing Group through non-public agreement transfer at 8.82 yuan per share, totaling 1.176 billion yuan.

**Xinqianglian**: September 30 is the last conversion day for "Qianglian Convertible Bonds"

Xinqianglian announced that as "Qianglian Convertible Bonds" have stopped trading, investors are reminded to convert within the deadline. September 30 is the last conversion day for "Qianglian Convertible Bonds," and holders can still convert before market close. After September 30 market close, remaining unconverted bonds will stop conversion and be mandatorily redeemed at 100.99 yuan per bond (including accrued interest at 1.00% annual rate). Investors may face losses if mandatorily redeemed.

**Lingyi iTech**: Planning H-share issuance and Hong Kong Stock Exchange listing

Lingyi iTech announced it is planning overseas share issuance (H-shares) and Hong Kong Stock Exchange listing. Currently discussing relevant work with intermediaries, with details undetermined. The H-share issuance and listing will not change the company's controlling shareholder and actual controller.

**Changchun High & New Technology**: Submitted H-share issuance and listing application to Hong Kong Stock Exchange

Changchun High & New Technology announced submitting H-share issuance and Hong Kong Stock Exchange main board listing application on September 29, 2025, with application materials published on the Hong Kong Stock Exchange website.

**Weili Transmission**: No significant changes in internal and external operating environment

Weili Transmission announced unusual stock trading fluctuations, stating no significant changes in current operations or internal/external operating environment. After verification, the company, controlling shareholder, and actual controller have no undisclosed material matters or matters under planning.

**Yicheng New Energy**: No undisclosed material matters

Yicheng New Energy announced stock price fluctuations, noting that on September 25, the company disclosed a strategic reorganization prompt regarding controlling shareholder. Henan Provincial Committee and Government decided to implement strategic reorganization of controlling shareholder China Pingmei Shenma Holding Group and Henan Energy Group. This reorganization will not significantly impact company operations, with Henan SASAC remaining as actual controller and no change in control. No undisclosed material matters exist.

**Changjiang Securities**: Received CSRC approval for public corporate bond issuance to professional investors

Changjiang Securities announced receiving CSRC approval for public corporate bond issuance to professional investors up to 20 billion yuan in face value.

**Bory Pharmaceutical**: BGM1812 injection for overweight/obesity treatment approved by US FDA for clinical trials

Bory Pharmaceutical announced US FDA approval for Phase I clinical trials of BGM1812 injection for overweight/obesity treatment. BGM1812 injection is a novel long-acting Amylin analog with good molecular activity and pharmaceutical stability.

**Hengrui Medicine**: Received multiple drug clinical trial approval notices

Hengrui Medicine announced subsidiaries received clinical trial approval notices from NMPA for SHR-7787 injection, SHR-4849 injection, bevacizumab injection, adebrelimab injection, and HRS-2129 tablets, with clinical trials to commence soon.

**Chong's Pharmaceutical**: Controlled subsidiary received Phase III clinical trial ethics approval for innovative drug Angladewe granules

Chong's Pharmaceutical announced controlled subsidiary Guangdong Chong's Ruichuang Biotechnology received ethics approval from Beijing Children's Hospital Ethics Committee for Phase III clinical trial of innovative drug Angladewe granules for 2-11 years old children with simple influenza A.

**Sinovac Pharma**: GB10 injection clinical trial registration application accepted

Sinovac Pharma announced wholly-owned subsidiary Shenzhen Sinovac received NMPA acceptance notice for "GB10 injection" clinical trial application for treating age-related macular degeneration (nAMD) and diabetic macular edema (DME).

**Shijing Technology**: Signed cooperation agreement with state-owned institutions

Shijing Technology announced signing cooperation agreement with Suzhou Xingtai Industrial Development, Suzhou Yangchenghu Digital Cultural Creative Park Investment, and Suzhou Surun Enterprise Consulting Management to address liquidity difficulties through establishing special purpose vehicle (SPV) with 301 million yuan registered capital for bailout support up to 300 million yuan in two phases.

**Performance Outlook**

**Yinglian Shares**: Q1-Q3 net profit expected to increase 1531.13%-1672.97% year-on-year

Yinglian Shares forecasted Q1-Q3 net profit of 34.5-37.5 million yuan, up 1531.13%-1672.97% year-on-year, mainly from fast-moving consumer goods metal packaging easy-open lid segment.

**Major Contracts**

**CRRC**: Recently signed major contracts totaling approximately 54.34 billion yuan

CRRC announced signing major contracts totaling approximately 54.34 billion yuan from July-September 2025, representing about 22% of 2024 operating revenue under Chinese accounting standards.

**Overseas Chinese Bank**: Confirmed as first bidder for approximately 512 million yuan sanitation project

Overseas Chinese Bank was selected as first bidder for Laishui County urban sanitation integration cooperation project with 20.4981 million yuan/year bid price for 25-year service period, totaling approximately 512 million yuan.

**China Construction**: Recently obtained two major projects

China Construction announced obtaining two major projects totaling 6.22 billion yuan, representing 0.3% of 2024 audited operating revenue.

**Huaqin Technology**: Signed 402 million yuan sales contract

Huaqin Technology announced signing two sales contracts totaling 402 million yuan (including tax) for batch-produced and R&D project special functional materials.

**Daoshi Intelligent**: Smart hospital project contract amount 113 million yuan

Daoshi Intelligent announced subsidiary Jiangsu Daoshi Jiuxin Medical Technology signed formal contract with China Construction Second Engineering Bureau for Lingang New Area Nicheng Community Pudong Hospital Lingang Campus purification project worth 113 million yuan.

**Share Changes**

**Zhiyang Innovation**: Controlling shareholder and concert parties plan to reduce holdings by no more than 1.8239%

Zhiyang Innovation announced controlling shareholder Zhiyang Holdings and concert party Zhiyang Investment plan to reduce holdings by no more than 4.225 million shares (no more than 1.8239% of total share capital) through centralized bidding and block trading.

**Andeli**: Shareholder plans to reduce holdings by no more than 1%

Andeli announced shareholder Donghua Fruit Industry Co., Ltd. (holding 17.23%) plans to reduce holdings by no more than 3.412 million shares (no more than 1% of total share capital) through centralized bidding.

**Sinomach Heavy Industry**: Shareholders plan to jointly reduce holdings by no more than 1%

Sinomach Heavy Industry announced concert parties Bank of China Deyang Branch and Bank of China Zhenjiang Runzhou Branch (jointly holding 5.95%) plan to reduce holdings by no more than 72.1355 million shares (no more than 1% of total share capital).

**Novosense**: Shareholder plans to reduce holdings by no more than 1%

Novosense announced shareholder Kehong Core (Hong Kong) Limited (holding 6.23%) plans to reduce holdings by no more than 4.595294 million shares (no more than 1% of total share capital).

**Meixin Semiconductor**: Shareholder plans to reduce holdings by no more than 1%

Meixin Semiconductor announced shareholder WIHARPER FUND VII HONG KONG LIMITED (holding 5.59%) plans to reduce holdings by no more than 1.1154 million shares (no more than 1% of total share capital).

**Zhongrun Optics**: Director plans to reduce holdings by no more than 695,300 shares

Zhongrun Optics announced director Lu Gaofei plans to reduce holdings by no more than 695,300 shares (no more than 0.7832% of total share capital).

**Zhongyan Shares**: Core technical personnel plans to reduce holdings by no more than 23,000 shares

Zhongyan Shares announced core technical personnel Ping Shiheng plans to reduce holdings by no more than 23,000 shares (no more than 0.0189% of total share capital).

**Share Buybacks**

**Fujirui**: Chairman proposes 10-20 million yuan share buyback

Fujirui announced actual controller, controlling shareholder, chairman and general manager Huang Fuyuan proposes 10-20 million yuan share buyback for future employee stock ownership plans or equity incentives, to be transferred within 3 years after completion.